CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.2.2.1. Competitive intelligence of companies and their strategies
3.3. TOP PLAYER POSITIONING, 2016
3.4. MARKET DYNAMICS
3.4.1. Drivers
3.4.1.1. Rise in incidence of risk factors that lead to blockage of blood vessels
3.4.1.2. Increase in geriatric population
3.4.1.3. Technological advancements
3.4.1.4. Lifestyle changes leading to blockage of blood vessels
3.4.2. Restraints
3.4.2.1. High cost of treatment
3.4.2.2. Complications associated with prosthetic grafts
3.4.3. Opportunities
3.4.3.1. Growth opportunities in emerging markets
3.4.3.2. Increase in awareness for vascular grafts
3.4.4. Impact analysis
3.5. CLINICAL TRIALS
CHAPTER 4 GLOBAL VASCULAR GRAFT MARKET, BY TYPE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. HEMODIALYSIS ACCESS GRAFT
4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.3. ENDOVASCULAR ANEURYSM REPAIR STENT GRAFTS
4.3.1. Abdominal Aortic Aneurysm (AAA)
4.3.2. Thoracic Aortic Aneurysm (TAA)
4.3.3. Key market trends
4.3.4. Key growth factors and opportunities
4.3.5. Market size and forecast
4.4. PERIPHERAL VASCULAR GRAFT
4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast
CHAPTER 5 VASCULAR GRAFT MARKET, BY RAW MATERIAL
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. POLYESTER
5.2.1. Market size and forecast
5.3. POLYTETRAFLUOROETHYLENE (PTFE)
5.3.1. Market size and forecast
5.4. POLYURETHANE
5.4.1. Market size and forecast
5.5. BIOSYNTHETIC
5.5.1. Market size and forecast
CHAPTER 6 VASCULAR GRAFT MARKET, BY END USER
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. HOSPITALS
6.2.1. Market size and forecast
6.3. AMBULATORY SURGICAL CENTERS (ASCS)
6.3.1. Market size and forecast
CHAPTER 7 VASCULAR GRAFT MARKET, BY REGION
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. NORTH AMERICA
7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.4. U.S.
7.2.5. Canada
7.2.6. Mexico
7.3. EUROPE
7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.4. Germany
7.3.5. France
7.3.6. UK
7.3.7. Italy
7.3.8. Spain
7.3.9. Rest of Europe
7.4. ASIA-PACIFIC
7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast
7.4.4. Japan
7.4.5. China
7.4.6. India
7.4.7. South Korea
7.4.8. Australia
7.4.9. Rest of Asia-Pacific
7.5. LAMEA
7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.4. Brazil
7.5.5. South Africa
7.5.6. Saudi Arabia
7.5.7. Rest of LAMEA
CHAPTER 8 COMPANY PROFILES
8.1. B. BRAUN MELSUNGEN AG
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.8. Key strategic moves and developments
8.2. C. R. BARD, INC.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Key strategic moves and developments
8.3. CARDINAL HEALTH INC.
8.3.1. Company overview
8.3.2. Company Snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.8. Key strategic moves and developments
8.4. COOK MEDICAL INC.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Key strategic moves and developments
8.5. ENDOLOGIX INC.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.8. Key strategic moves and developments
8.6. LEMAITRE VASCULAR, INC.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.8. Key strategic moves and developments
8.7. MAQUET HOLDING B.V. & CO. KG
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Key strategic moves and developments
8.8. MEDTRONIC PLC
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Key strategic moves and developments
8.9. TERUMO CORPORATION
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating product categories
8.9.4. Product portfolio
8.9.5. Business performance
8.9.8. Key strategic moves and developments
8.10. W. L. GORE & ASSOCIATES, INC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio